Icosagen’s proprietary QMCF Technology is established
for expression of biologically active substances, such as recombinant
proteins, recombinant antibodies, virus like particles (VLPs); and for
expression of proteins of interest in cell-based assays of the putative
drug substance.
Reference: Silla, et al Episomal maintenance of plasmids with hybrid origins in mouse cells. J. Virol 2005 Dec; 79 (24) 15277-88.
QMCF technology uses mammalian cells and
appropriate plasmids. QMCF plasmids are based on mouse polyomavirus (Py) DNA
replication origin which in combination with Ebstein-Barr virus (EBV) EBNA-1
protein binding site as nuclear retention elements can ensure stable
propagation of plasmids in mammalian cells. To support stable maintenance and
partitioning of QMCF plasmids combination of two proteins Ebstein-Barr virus
(EBV) EBNA-1 and Py Large-T antigen have to be expressed in QMCF cell lines.
QMCF technology uses stable eukaryotic cell lines based on U2OS, HEK293 and CHO
cell lines. All cell lines express Py Large-T protein for replication and EBV
EBNA-1 protein for maintenance of plasmid.
Keywords:
- Usage of stable, multicopy episomal expression, no need for chromosomal integration;
- Quick production - 5 weeks from cDNA to small scale (1mg) of recombinant protein, monoclonal antibody, VLP;
- Easy upscale of production: generation of cell banks, fast scale-up up to 1 g of protein, antibody or VLP;
- Quick construction - 5 weeks from cDNA to cell-based assay.
Reference: Silla, et al Episomal maintenance of plasmids with hybrid origins in mouse cells. J. Virol 2005 Dec; 79 (24) 15277-88.
